Solaris Asset Management Has Upped By $600,756 Its Darden Restaurants (DRI) Stake; Shorts at TG Therapeutics (TGTX) Lowered By 11.25%

February 19, 2018 - By John Hoffman

Solaris Asset Management Llc increased Darden Restaurants Inc (DRI) stake by 169.27% reported in 2017Q3 SEC filing. Solaris Asset Management Llc acquired 7,702 shares as Darden Restaurants Inc (DRI)’s stock rose 13.33%. The Solaris Asset Management Llc holds 12,252 shares with $965,000 value, up from 4,550 last quarter. Darden Restaurants Inc now has $11.92 billion valuation. The stock decreased 1.20% or $1.17 during the last trading session, reaching $96.52. About 1.24 million shares traded. Darden Restaurants, Inc. (NYSE:DRI) has risen 31.96% since February 19, 2017 and is uptrending. It has outperformed by 15.26% the S&P500.

TG Therapeutics Incorporated (NASDAQ:TGTX) had a decrease of 11.25% in short interest. TGTX’s SI was 15.88 million shares in February as released by FINRA. Its down 11.25% from 17.89 million shares previously. With 1.40 million avg volume, 11 days are for TG Therapeutics Incorporated (NASDAQ:TGTX)’s short sellers to cover TGTX’s short positions. The SI to TG Therapeutics Incorporated’s float is 47.31%. The stock decreased 3.56% or $0.45 during the last trading session, reaching $12.2. About 1.19 million shares traded. TG Therapeutics, Inc. (NASDAQ:TGTX) has risen 60.54% since February 19, 2017 and is uptrending. It has outperformed by 43.84% the S&P500.

Since December 29, 2017, it had 0 buys, and 1 insider sale for $272,051 activity. Power Sean A sold $272,051 worth of stock or 32,006 shares.

Investors sentiment decreased to 1.21 in 2017 Q3. Its down 1.07, from 2.28 in 2017Q2. It fall, as 11 investors sold TG Therapeutics, Inc. shares while 22 reduced holdings. 11 funds opened positions while 29 raised stakes. 35.13 million shares or 3.60% more from 33.91 million shares in 2017Q2 were reported. Bessemer Grp Inc holds 1,403 shares or 0% of its portfolio. Jennison Lc holds 1.24 million shares or 0.02% of its portfolio. 600 are held by Pnc Financial Group. Senzar Asset Management Ltd Liability reported 863,500 shares or 2.5% of all its holdings. Ubs Asset Mngmt Americas reported 0.01% of its portfolio in TG Therapeutics, Inc. (NASDAQ:TGTX). Credit Suisse Ag holds 0% or 224,066 shares. Columbus Circle accumulated 1.53 million shares. Ameriprise Fin invested 0% of its portfolio in TG Therapeutics, Inc. (NASDAQ:TGTX). Tiaa Cref Inv Ltd Com accumulated 0% or 122,638 shares. Tudor Investment Corp Et Al reported 0.01% stake. 4 are held by Willingdon Wealth. Geode Mgmt Lc stated it has 453,571 shares or 0% of all its holdings. 64,306 were reported by Deutsche Bank Ag. Ra Llc accumulated 700,000 shares or 0.75% of the stock. Susquehanna International Gru Llp has 187,878 shares.

Among 8 analysts covering TG Therapeutics (NASDAQ:TGTX), 8 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. TG Therapeutics had 19 analyst reports since August 12, 2015 according to SRatingsIntel. The firm has “Buy” rating by Jefferies given on Monday, June 5. The firm has “Buy” rating given on Wednesday, January 17 by FBR Capital. The company was maintained on Monday, December 11 by FBR Capital. Suntrust Robinson initiated the stock with “Buy” rating in Friday, May 27 report. FBR Capital initiated TG Therapeutics, Inc. (NASDAQ:TGTX) rating on Tuesday, December 1. FBR Capital has “Outperform” rating and $29 target. The rating was upgraded by Zacks to “Hold” on Wednesday, August 12. On Wednesday, August 12 the stock rating was reinitiated by H.C. Wainwright with “Buy”. The rating was maintained by FBR Capital with “Buy” on Thursday, June 15. The stock has “Buy” rating by H.C. Wainwright on Monday, December 11. As per Friday, May 27, the company rating was initiated by SunTrust.

TG Therapeutics, Inc., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases primarily in the United States. The company has market cap of $861.96 million. It develops TG-1101 , a chimeric, glycoengineered monoclonal antibody that targets an epitope on the CD20 antigen found on the surface of B-lymphocytes developed to aid in the depletion of circulating B-cells; and TG-1101 in combination with TGR-1202 for relapsed/refractory non-HodgkinÂ’s lymphoma and chronic lymphocytic leukemia. It currently has negative earnings. The firm also develops TGR-1202, an orally available phosphoinositide-3-kinase delta inhibitor with nanomolar potency to the delta isoform and high selectivity over the alpha, beta, and gamma isoforms, as well as for hematologic malignancies.

Investors sentiment increased to 0.96 in Q3 2017. Its up 0.01, from 0.95 in 2017Q2. It improved, as 55 investors sold DRI shares while 169 reduced holdings. 56 funds opened positions while 160 raised stakes. 108.03 million shares or 1.09% more from 106.87 million shares in 2017Q2 were reported. Smithfield Trust holds 70 shares or 0% of its portfolio. Capital Fincl Advisers Limited Liability Corporation invested in 10,808 shares or 0.01% of the stock. Morgan Stanley invested 0.02% in Darden Restaurants, Inc. (NYSE:DRI). Dnb Asset Mngmt As holds 11,933 shares or 0.01% of its portfolio. Ngam Advisors Ltd Partnership invested in 10,549 shares. Assetmark holds 5,718 shares. The New York-based Evercore Tru Na has invested 0.62% in Darden Restaurants, Inc. (NYSE:DRI). Huntington Financial Bank holds 0% or 1,623 shares in its portfolio. Citadel Advsr Limited Liability Corp invested in 265,256 shares. Moreover, Federated Invsts Pa has 0% invested in Darden Restaurants, Inc. (NYSE:DRI) for 2,253 shares. Bancorp Of America De stated it has 1.03 million shares. Enterprise Fincl Corp invested 0.06% in Darden Restaurants, Inc. (NYSE:DRI). Profund Advisors Limited Company, Maryland-based fund reported 3,592 shares. San Francisco Sentry Gp (Ca) invested 0.06% in Darden Restaurants, Inc. (NYSE:DRI). Commonwealth Bancorp Of holds 16,913 shares.

Among 26 analysts covering Darden Restaurants (NYSE:DRI), 12 have Buy rating, 0 Sell and 14 Hold. Therefore 46% are positive. Darden Restaurants had 97 analyst reports since August 25, 2015 according to SRatingsIntel. The firm earned “Market Perform” rating on Thursday, October 19 by BMO Capital Markets. The stock has “Sell” rating by Stifel Nicolaus on Monday, October 3. The stock of Darden Restaurants, Inc. (NYSE:DRI) earned “Market Perform” rating by Wells Fargo on Wednesday, September 27. Citigroup maintained Darden Restaurants, Inc. (NYSE:DRI) rating on Monday, April 18. Citigroup has “Buy” rating and $75 target. RBC Capital Markets maintained the shares of DRI in report on Thursday, December 21 with “Hold” rating. The rating was maintained by BTIG Research on Wednesday, April 6 with “Buy”. The firm earned “Hold” rating on Friday, October 13 by Longbow. Oppenheimer maintained Darden Restaurants, Inc. (NYSE:DRI) on Monday, June 26 with “Buy” rating. Bernstein initiated Darden Restaurants, Inc. (NYSE:DRI) on Thursday, May 26 with “Market Perform” rating. The stock has “Hold” rating by SunTrust on Tuesday, January 2.